Company intelligence / Profile preview

Gardant Pharmaceuticals

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Gardant Pharmaceuticals was a drug development company that operated as a Pharmaceutical Development Organization (PDO), acquiring and advancing early-stage clinical products. Formerly known as Bioaccelerate Holdings, the company was renamed in 2006 and focused on therapeutic areas such as oncology, central nervous system disorders, and cardiovascular disease. Its lead program, RP101 (brivudine), was a small molecule inhibitor of heat shock protein 70 (HSP70) being evaluated in Phase 2 clinical trials for the treatment of pancreatic cancer. The company was eventually acquired by Switch Pharma and is no longer active.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Newport PharmaceuticalsRESprotect GmbH

Beyond the preview

Go deeper on Gardant Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gardant Pharmaceuticals.

Explore the full profile